ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2517

Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS

Hakan Babaoglu1, Jessica Li 2, Daniel Goldman 3, Laurence Magder 4 and Michelle Petri 2, 1Gazi University School of Medicine, Ankara, Turkey, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4University of Maryland School of Medicine, Baltimore, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: hydroxychloroquine and Disease Activity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a potential treat to target goal in systemic lupus erythematosus (SLE), has been found to correlate with reduced damage accrual in SLE. In particular, SLE patients, in LLDAS for more than half of the observation time, have a lower risk of new damage. We identified predictors of being in LLDAS over 50% of the observation time.

Methods: This analysis was based on cohort data from its inception until May, 2019. A total of 2363 SLE patients, diagnosed according to the SLICC or ACR classification criteria and with at least two clinical visits, were included. We applied the definition of LLDAS and determined whether LLDAS was satisfied at each visit for each patient. Then, each observation for each patient was defined based on the status at the following visits throughout the whole follow up. Follow up visits that occurred after a gap of more than 12 months (+/- 1 month) between clinic visits were excluded. Percentage of time in LLDAS was calculated. Durable LLDAS was defined as being in LLDAS for over 50% of the observation time. Patients were then classified into groups based on whether they had durable LLDAS or not. We analyzed the predictors of durable LLDAS from the stepwise selection procedure in logistic regression.

Results: Ninety-two percent of the patients were female, 40.2% African-American, and 51.9% Caucasian. 50% of the patients were diagnosed with SLE under the age of 30 years, 25% were between the age of 30 and 40, 14.5% were between 40 and 50, and 10.5% were diagnosed at age of 50 and over. 1198 (50.6%) patients overall, including 35.2% of African-Americans, achieved durable LLDAS. Patients with durable LLDAS, were significantly older at diagnosis, more educated, had longer disease duration, and were less likely to be African-American (Table 1,2). In the multivariable model, African-American ethnicity, ever having low C3, subacute cutaneous lupus erythematosus, alopecia, renal insufficiency, anti-RNP positivity, % of time with immunosuppressant use, and mean prednisone dose remained negative predictors, while age at diagnosis, disease duration, hemolytic anemia and higher % of time with hydroxychloroquine use remained positive predictors of durable LLDAS (Table 3).

Conclusion: A higher percentage of time with hydroxychloroquine use is a modifiable predictor of durable LLDAS, even after adjustment for clinical, demographic and other treatment variables. Only one third of African-American patients achieved durable LLDAS. Hydroxychloroquine use (and demonstration of adherence) remains essential in both clinical practice and in randomized clinical trials.


Abstract-LLDAS durationv3withoutrefheatmapsplittables-Table1

Patients demographics and laboratory characteristics, grouped according to percentage of time in LLDAS


Abstract-LLDAS durationv3withoutrefheatmapsplittables-Table2

Clinical manifestations of patients, grouped according to percentage of time in LLDAS


Abstract-LLDAS durationv3withoutrefheatmapsplittables-Table3

Predictors for Durable LLDAS


Disclosure: H. Babaoglu, None; J. Li, None; D. Goldman, None; L. Magder, None; M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5.

To cite this abstract in AMA style:

Babaoglu H, Li J, Goldman D, Magder L, Petri M. Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/hydroxychloroquine-is-a-modifiable-predictor-of-durable-lldas/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hydroxychloroquine-is-a-modifiable-predictor-of-durable-lldas/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.